[Preclinical and clinical properties of vaniprevir (VANIHEP® Capsules 150 mg), a novel therapeutic agent for hepatitis C].
Kiyoshi
K
Kinoshita
Takashi
T
Iwasa
Akiko
A
Takase
Keisuke
K
Nakamura
D000998:Antiviral Agents / Q000737:chemistry / Q000627:therapeutic use*; D002214:Capsules / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000627:therapeutic use*; D054833:Isoindoles; D047029:Lactams, Macrocyclic; D007930:Leucine / Q000031:analogs & derivatives; D011392:Proline / Q000031:analogs & derivatives; D013449:Sulfonamides
D000998:Antiviral Agents; D002214:Capsules; D003521:Cyclopropanes; D007211:Indoles; D054833:Isoindoles; D047029:Lactams, Macrocyclic; D013449:Sulfonamides; D011392:Proline; C540393:vaniprevir; D007930:Leucine